Granada

• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca … Recruiting
  2024-519901-36-00 5 2025-12-17 Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
• Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testi … Recruiting
  2025-521780-12-00 11 2025-12-16 Non-ischemic cardiomyopathy
• Phase 2 Study of LAD191 in Adults With Hidradenitis Suppurativa Recruiting
  2025-521293-34-00 4 2025-12-09 Moderate-to-severe hidradenitis suppurativa
• A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma … Recruiting
  2024-512029-10-00 5 2025-12-05 Intermediate risk, non-muscle invasive bladder cancer
• Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded … Recruiting
  2025-521251-24-00 4 2025-12-01 Non-Small cell lung cancer (NSCLC)
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t … Recruiting
  2024-519479-24-00 4 2025-11-21 metastatic colorectal cancer
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with … Recruiting
  2024-518976-30-00 3 2025-07-02 Systemic lupus erythematosus
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD Recruiting
  2023-509370-39-00 5 2025-06-03 connective tissue diseases
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso … Recruiting
  2024-515706-77-00 5 2025-05-08 Moderate to Severe Plaque Psoriasis
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a … Recruiting
  2023-505172-29-00 4 2025-04-24 Resectable Non-small Cell Lung Cancer
• A study of the efficacy and safety of Belimumab in adults with interstitial lung disease associated with connective tissue disease. Recruiting
  2024-513018-36-00 5 2025-03-06 Lung Diseases, Interstitial
• Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed … Recruiting
  2024-512484-31-00 4 2025-02-28 FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach
• A trial to investigate teprotumumab mg/ml subcutaneous administration compared with placebo in male and female adult participants with moder … Recruiting
  2024-515702-63-00 5 2025-02-20 Moderate-to-Severe Active Thyroid Eye Disease
• LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of … Recruiting
  2024-513356-15-00 5 2024-12-30 Acquired Blepharoptosis
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic … Recruiting
  2024-512423-36-00 5 2024-11-20 Undifferentiated pleomorphic sarcoma
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma

Showing 49–72 of 382 trials